Linfoma angioinmunoblástico T con linfoma secundario B difuso de célula grande EBV+ de localización uretralreporte de un caso

  1. Irene Ruiz Adelantado
  2. Clara Sáez Ibarra
  3. Laura Noguera Alonso
  4. Lorenzo Alarcón García
Revue:
Revista Sanitaria de Investigación

ISSN: 2660-7085

Année de publication: 2024

Volumen: 5

Número: 5

Type: Article

DIALNET GOOGLE SCHOLAR lock_openAccès ouvert editor

D'autres publications dans: Revista Sanitaria de Investigación

Résumé

Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma that can lead to the development of secondary neoplasms, given its association with EBV-positive immunoblastic cells that can expand as a consequence of an immunosuppressed state. Case Report: A 79-year-old woman with a personal history of myelodysplastic syndrome presents to the emergency department with a sensation of generalized discomfort. Imaging tests reveal polyadenopathies in various lymph node territories. An axillary lymph node biopsy confirms a diagnosis of AITL with a watchful waiting approach. She returns to the emergency department one year later with a foul-smelling urethral nodule causing difficulty urinating, with no other accompanying symptoms. The biopsy result of the urethral lesion is consistent with an EBV-associated diffuse large B-cell lymphoma (LBDCG). Discussion: Patients with AITL have a higher predisposition to develop secondary neoplasms due to the immune dysregulation associated with this type of lesion. The secondary lymphomas developed may be found in the same location as the first or in a completely different one, with extranodal localization being rare and associated with worse prognoses. The majority of secondary lymphomas are diffuse large B-cell lymphomas, and many of them are associated with EBV. In these tumors, it is postulated that the virus serves as a stimulus for B cells, predisposing them to neoplastic transformation.

Références bibliographiques

  • Yang, QX., Pei, XJ., Tian, XY. et al. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature. Diagn Pathol 7, 7 (2012).
  • Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, Muller-Hermelink HK. Non-Hodgkin’s Lymphoma Classification Project: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13(1):140–149.
  • Xu Y, McKenna RW, Hoang MP, Collins RH, Kroft SH. Composite angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma: a case report and review of the literature. Am J Clin Pathol. 2002;118(6):848-854.
  • Zhou Y, Rosenblum MK, Dogan A, Jungbluth AA, Chiu A. Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma. J Hematop. 2015;8(4):235-241. doi:10.1007/s12308-015-0241-8
  • Poon F, Ieremia E, Collins G, Matin RN. Epstein-Barr Virus-Induced Cutaneous Diffuse Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma. Am J Dermatopathol. 2019;41(12):927-930.
  • Magro C.M., Ruan J., Grossman M., Hedayat A.A. Monoclonal plasma cell infiltrates in the setting of cutaneous follicular helper T cell lymphoproliferative disorders. Ann Diagn Pathol. 2019;40:94–104.
  • Şimşek C., Bostankolu B., Özoğul E., Sağlam Ayhan A., Üner A., Büyükaşık Y. EBV-related diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. Turk J Haematol. 2019;36(1):57–59.
  • Eladl AE, Shimada K, Suzuki Y, Takahara T, Kato S, Kohno K, Elsayed AA, Wu CC, Tokunaga T, Kinoshita T, Sakata-Yanagimoto M, Nakamura S, Satou A. EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma. Cancer Med. 2020 Jan;9(2):678-688.
  • Grossman M, Ruan J, Magro C. Epstein-Barr virus-positive, CD30-positive, diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. JAAD Case Rep. 2022 May 13;25:58-62.
  • Eladl AE, Shimada K, Suzuki Y, Takahara T, Kato S, Kohno K, Elsayed AA, Wu CC, Tokunaga T, Kinoshita T, Sakata-Yanagimoto M, Nakamura S, Satou A. EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma. Cancer Med. 2020 Jan;9(2):678-688.
  • Zettl A, Lee SS, Rüdiger T, Starostik P, Marino M, Kirchner T, et al. Epstein-Barr virus-associated B-cell lymphoprolifera-tive disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002; 117: 368–379.
  • Takahashi T, Maruyama R, Mishima S, Inoue M, Kawakami K, Onishi C, et al. Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. J Clin Exp Hematop 2010; 50: 59–63.
  • Park S, Noguera ME, Brière J, Feuillard J, Cayuela JM, Sigaux F, et al. Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous trans-plantation for angioimmunoblastic T-cell lymphoma. Hematol J 2002; 3: 317–320.
  • Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M. Epstein-Barr virus-associated B-cell lymp-homa secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol 2008; 88: 434–440.
La source de données: Dialnet